Aticaprant Kappa Opioid Antagonist for Treatment-Resistant Depression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for major depressive disorder, particularly in patients with moderate to severe anhedonia, often fail to provide adequate relief, leading to persistent symptoms and side effects from antidepressants such as weight gain and sexual dysfunction.
Innovation Solution
Administration of aticaprant, either alone or in combination with other antidepressants, to effectively manage depression and anhedonia while minimizing side effects like weight gain and sexual dysfunction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional antidepressants (SSRI, SNRI) are administered to treat major depressive disorder, then depressive symptoms are partially relieved, but anhedonia symptoms persist and side effects such as weight gain and sexual dysfunction occur
Solution Approach 1:
The patent changes the pharmacological target parameter from serotonin/norepinephrine reuptake inhibition to kappa opioid receptor antagonism. This fundamental parameter change in mechanism of action allows aticaprant to treat depression through a different pathway, potentially avoiding the side effect profile associated with traditional antidepressants while maintaining therapeutic effectiveness.
Solution Approach 2:
The patent extracts and addresses the specific subset of depression symptoms related to anhedonia by targeting the kappa opioid receptor pathway, which is distinct from the general antidepressant mechanism. This extraction approach focuses treatment on the specific pathological pathway involved in anhedonia while leaving other neurotransmitter systems less affected.
2Reliability
If traditional antidepressants are used as adjunctive treatment, then some depressive symptoms improve, but response rate remains limited at about 50% with substantial persistent impairment in many patients
Solution Approach 1:
The patent introduces aticaprant as an intermediary substance that acts on the kappa opioid receptor pathway, which is distinct from the serotonin and norepinephrine systems targeted by traditional antidepressants. This intermediary approach provides an additional therapeutic mechanism that can work independently or complementarily with existing antidepressants, thereby increasing overall response rates.
Solution Approach 2:
The patent employs composite treatment strategies combining aticaprant with traditional antidepressants (SSRI, SNRI) to create a multi-mechanism therapeutic approach. This composite approach leverages the different mechanisms of action to achieve synergistic effects, addressing both the limitations of monotherapy and the high rate of treatment failure.
3Object-affected harmful factors
If chronic stress and substance abuse lead to increased dynorphin expression and KOR activation, then negative affective states are produced, but traditional antidepressants do not adequately address this pathway
Solution Approach 1:
The patent converts the harmful effect of dynorphin-KOR interaction into a therapeutic opportunity by using aticaprant as a KOR antagonist. Instead of trying to reduce dynorphin expression directly, the invention blocks the harmful downstream effects at the KOR level, thereby converting the pathological pathway into a target for beneficial intervention.
Solution Approach 2:
The patent extracts and isolates the kappa opioid receptor pathway as a specific therapeutic target, separating it from the broader antidepressant mechanisms. This extraction allows for targeted intervention in the stress-response pathway involving dynorphin and KOR, addressing the specific mechanism underlying stress-related negative affective states.
Data Source
AI summary
The disclosure provides methods for treating major depressive disorder in a human patient having moderate or severe anhedonia. The methods comprise administering to the patient in need thereof an effective amount of aticaprant, or a pharmaceutically acceptable salt thereof. In some embodiments, the patient had an inadequate response to other antidepressant therapy prior to treatment with aticaprant. In other embodiments, the other antidepressant therapy comprised a selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), or a combination thereof.